Keywords: Pernix Therapeutics, Cypress Pharma, Hawthorn Pharma, M&A, Third-quarter results
Pernix splashes out over $100 million to buy Cypress Pharma and Hawthorn Pharma
Article | 15 November 2012
US specialty drugmaker Pernix Therapeutics (NYSE: PTX) has entered into a definitive agreement to acquire privately-held Cypress Pharmaceuticals, a maker ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
